What's top-of-mind for biopharma executives in 2023?
Many life science professionals say they are ‘cautiously positive’ about the outlook for their industry in 2023, although highlight it won’t be all plain sailing.
Archives for January 17, 2023
China approves Bio-Thera Solutions' biosimilar to Actemra
The China National Medical Products Administration (NMPA) has approved BAT1806, a biosimilar of Actemra (tocilizumab), in China.
UK ATMP clinical research picture remains positive despite challenging global environment
In 2022, the UK continued to have a signficant footprint in ATMP clinical research, with total ongoing trials increasing from 168 in 2021 to 178 in 2022, according to a new report.
Resilience to expand global footprint, collaborating on first GMP biopharma facility in UAE
National Resilience has secured an equity investment from Mubadala, an Abu Dhabi sovereign investor. The amount was not disclosed.